Skip to Main Content

Amid ongoing concerns over the cost of insulin, a leading physicians group is calling for a raft of measures that would increase affordability for the life-saving diabetes treatment, a move that comes as the incoming Biden administration readies its agenda for addressing prescription drug prices.

At the top of its list, the Endocrine Society would like to see the federal government negotiate pricing with drug companies, as well as place limits on future wholesale price hikes that are tied to the overall inflation rate and restrict the out-of-pocket costs borne by people with diabetes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!